Ekaterina Moroz1, Randy A Albrecht2, Brandon Aden1, Ann Bordwine Beeder1, Jianda Yuan3, Adolfo García-Sastre4, Brian R Edlin5, Mirella Salvatore6. 1. Department of Medicine, Weill Cornell Medical College, US. 2. Department of Microbiology, Icahn School of Medicine at Mount Sinai, US; Global Health and Emerging Pathogens Institute, Icahn School of Medicine Mount Sinai, US. 3. Immune Monitoring Facility, Ludwig Center for Center Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, US. 4. Department of Microbiology, Icahn School of Medicine at Mount Sinai, US; Global Health and Emerging Pathogens Institute, Icahn School of Medicine Mount Sinai, US; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, US. 5. Department of Medicine, Weill Cornell Medical College, US; Institute for Infectious Disease Research, National Development and Research Institutes, New York, NY, US. 6. Department of Medicine, Weill Cornell Medical College, US. Electronic address: mis2053@med.cornell.edu.
Abstract
BACKGROUND: Influenza vaccination is recommended for vulnerable individuals, including active drug users, to prevent influenza complications and decrease influenza spread. Recent studies suggest that opioids negatively regulate immune responses in experimental models, but the extent to which opioid use will affect the humoral responses to influenza vaccine in humans is unknown. This information is critical in maximizing vaccination efforts. OBJECTIVE: To determine whether there is a difference in antibody response after influenza vaccination in heroin or methadone users compared to control subjects. METHODS: We studied active heroin users, subjects on methadone maintenance treatment (MMT) and subjects that did not use any drugs before and 1 and 4 weeks after vaccination with trivalent influenza vaccine (TIV). We measured hemagglutination inhibition and microneutralization titers, and we compared geometric mean titers (GMT), and rates of seroprotection and seroconversion for each of the vaccine strains among the 3 groups of subjects. RESULTS: Heroin users, subjects on MMT and non-user controls mount a similarly robust serologic response to TIV. GMT and rates of seroprotection and seroconversion were not significantly different among groups. CONCLUSION: Our results suggest that opioid use do not significantly alter antibody responses to influenza vaccine supporting the vaccination effort in these populations.
BACKGROUND:Influenza vaccination is recommended for vulnerable individuals, including active drug users, to prevent influenza complications and decrease influenza spread. Recent studies suggest that opioids negatively regulate immune responses in experimental models, but the extent to which opioid use will affect the humoral responses to influenza vaccine in humans is unknown. This information is critical in maximizing vaccination efforts. OBJECTIVE: To determine whether there is a difference in antibody response after influenza vaccination in heroin or methadone users compared to control subjects. METHODS: We studied active heroin users, subjects on methadone maintenance treatment (MMT) and subjects that did not use any drugs before and 1 and 4 weeks after vaccination with trivalent influenza vaccine (TIV). We measured hemagglutination inhibition and microneutralization titers, and we compared geometric mean titers (GMT), and rates of seroprotection and seroconversion for each of the vaccine strains among the 3 groups of subjects. RESULTS:Heroin users, subjects on MMT and non-user controls mount a similarly robust serologic response to TIV. GMT and rates of seroprotection and seroconversion were not significantly different among groups. CONCLUSION: Our results suggest that opioid use do not significantly alter antibody responses to influenza vaccine supporting the vaccination effort in these populations.
Authors: Claire E Wilcox; Michael P Bogenschutz; Masato Nakazawa; George E Woody Journal: Am J Drug Alcohol Abuse Date: 2011-09-22 Impact factor: 3.829
Authors: J M Rodrigo; M A Serra; L Aparisi; A Escudero; M S Gilabert; F García; R Gonzalez; J A del Olmo; A H Wassel; A Artero Journal: Vaccine Date: 1992 Impact factor: 3.641
Authors: A M Iorio; A Alatri; D Francisci; R Preziosi; M Neri; I Donatelli; M R Castrucci; L R Biasio; C Tascini; R Iapoce; P Pierucci; F Baldelli Journal: Vaccine Date: 1997-01 Impact factor: 3.641
Authors: D M Novick; M Ochshorn; V Ghali; T S Croxson; W D Mercer; N Chiorazzi; M J Kreek Journal: J Pharmacol Exp Ther Date: 1989-08 Impact factor: 4.030
Authors: Sascha Dublin; Rod L Walker; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Michael Von Korff; Lisa A Jackson Journal: J Am Geriatr Soc Date: 2011-09-13 Impact factor: 5.562
Authors: M D Raleigh; S J Peterson; M Laudenbach; F Baruffaldi; F I Carroll; S D Comer; H A Navarro; T L Langston; S P Runyon; S Winston; M Pravetoni; P R Pentel Journal: PLoS One Date: 2017-12-01 Impact factor: 3.240